Perfusion Bioreactor With Artificial Intelligence (AI) Control Global Market Report 2025

The perfusion bioreactor with artificial intelligence (AI) control market size has grown exponentially in recent years. It will grow from $1.55 billion in 2024 to $1.88 billion in 2025 at a compound annual growth rate (CAGR) of 21.3%. The growth during the historic period can be attributed to the rising adoption of single use bioreactors, the increasing investment in biopharmaceutical research and development, the growing demand for efficient cell culture systems, the expanding focus on continuous bioprocessing approaches, and the increasing level of automation in manufacturing processes.

The perfusion bioreactor with artificial intelligence (AI) control market size is expected to see exponential growth in the next few years. It will grow to $4.02 billion in 2029 at a compound annual growth rate (CAGR) of 20.9%. The growth during the forecast period can be attributed to the rising adoption of digital health technologies, the growing preference for hybrid bioreactor solutions, the increasing demand for advanced monitoring systems, the expanding applications in personalized medicine, and the growing government support for bioprocessing innovation. Major trends during the forecast period include technological advancements in artificial intelligence driven control platforms, innovations in continuous bioprocessing methods, developments in automated monitoring and control systems, research and development in precision medicine applications, and the integration with digital manufacturing ecosystems.

The increasing adoption of personalized medicine is expected to drive the growth of the perfusion bioreactor with artificial intelligence control market in the coming years. Personalized medicine is a medical approach that tailors treatment to an individual’s genetic, molecular, and clinical characteristics for more accurate and effective care. The demand for personalized medicine is growing due to advances in genomics, which enable therapies customized to a patient’s genetic profile for improved efficacy and safety. Perfusion bioreactors with artificial intelligence control support personalized medicine by enabling precise, continuous production of patient-specific cells, such as stem cells or engineered tissues, under tightly regulated conditions. For example, in February 2024, according to the Personalized Medicine Coalition, a United States-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six approvals in 2022. These newly approved therapies included seven cancer drugs and three treatments for other diseases and conditions. Therefore, the growing adoption of personalized medicine is fueling the expansion of the perfusion bioreactor with artificial intelligence control market.

Leading companies in the perfusion bioreactor with artificial intelligence control market are focusing on developing innovative solutions such as artificial intelligence enhanced real-time bioprocess monitoring to optimize cell culture performance, improve product yield, and lower operational costs in biopharmaceutical manufacturing. Artificial intelligence enhanced real-time bioprocess monitoring involves the use of artificial intelligence algorithms to continuously analyze bioreactor data, providing real-time insights, predictive adjustments, and optimization of cell growth and product quality during biomanufacturing. For instance, in February 2025, The Cultivated B GmbH, a Germany-based biotechnology company, introduced artificial intelligence driven multi-channel biosensors to enhance real-time monitoring of bioreactors used in cell culture and fermentation processes. These biosensors provide continuous, high-resolution data analytics, enabling bioprocess engineers to track growth and metabolism with high sensitivity, detecting molecules at sub-picomolar levels such as glucose, amino acids, and lactic acid. The integration of artificial intelligence provides real-time insights and recommendations to optimize media formulation, enhance measurement accuracy, minimize contamination risk by removing manual sampling, and accelerate product development across pharmaceuticals, biologics, food biotechnology, waste upcycling, and alternative protein production.

In August 2025, Culture Biosciences Inc., a United States-based biotechnology company, partnered with Cytiva Bioscience Holding Ltd. to advance digital bioprocessing solutions. The partnership aims to accelerate and reduce risks in upstream bioprocess development by offering scalable, cloud-connected, and digitally integrated bioreactor systems that enable faster and more reliable therapeutic production from laboratory to commercial scale. Cytiva Bioscience Holding Ltd. is a United States-based biotechnology company that provides perfusion bioreactors with artificial intelligence control.

Major players in the perfusion bioreactor with artificial intelligence (ai) control market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza Group AG., Danaher Corporation, Sartorius Aktiengesellschaft, Getinge AB., WuXi Biologics Inc., Eppendorf Aktiengesellschaft, ABEC Inc., Catalyx.ai, PBS Biotech Inc., Cytovance Biologics, Culture Biosciences Inc., Esco Lifesciences Group Ltd., Cell Culture Company GmbH, Synthecon Inc., OmniBRx Biotechnologies Inc., ProlifeCell Inc., Sciperio Ltd., and The Cultivated B Ltd.

North America was the largest region in the perfusion bioreactor with artificial intelligence (AI) control market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in perfusion bioreactor with artificial intelligence (AI) control report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The perfusion bioreactor with artificial intelligence (AI) control market research report is one of a series of new reports that provides perfusion bioreactor with artificial intelligence (AI) control market statistics, including perfusion bioreactor with artificial intelligence (AI) control industry global market size, regional shares, competitors with a perfusion bioreactor with artificial intelligence (AI) control market share, detailed perfusion bioreactor with artificial intelligence (AI) control market segments, market trends and opportunities, and any further data you may need to thrive in the perfusion bioreactor with artificial intelligence (AI) control industry. This perfusion bioreactor with artificial intelligence (AI) control market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A perfusion bioreactor with artificial intelligence control is a bioreactor system designed for continuous cell culture that delivers fresh media and removes waste. Artificial intelligence monitors critical parameters and automatically adjusts conditions to optimize productivity, consistency, and efficiency in the manufacturing of biologics or cell-based products.

The main product types of perfusion bioreactors with artificial intelligence control include single-use perfusion bioreactors and multi-use perfusion bioreactors. Single-use perfusion bioreactors are disposable systems used for continuous cell culture that enhance scalability and minimize contamination risks in biomanufacturing. Artificial intelligence control features include predictive analytics, process optimization, real-time monitoring, automated feedback control, and others. These bioreactors are used in applications such as cell therapy, monoclonal antibody production, vaccine manufacturing, stem cell research, and others, and serve end users including biopharmaceutical companies, academic and research institutes, contract manufacturing organizations, and others.

The countries covered in the perfusion bioreactor with artificial intelligence (AI) control market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The perfusion bioreactor with artificial intelligence (AI) control market consists of revenues earned by entities by providing services such as cell culture management, nutrient and waste regulation, AI-driven process control, performance optimization, and automated data analytics. The market value includes the value of related goods sold by the service provider or included within the service offering. The perfusion bioreactor with artificial intelligence (AI) control market includes sales of automated perfusion bioreactor systems, hybrid perfusion bioreactors, and AI-integrated bench-scale perfusion bioreactors. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.